Radiosensitizing effect of gold nanoparticle loaded with small interfering RNA-SP1 on lung cancer

Zhou, Ming; Jiang, Shan; Gu, Anxin; Chen, Xuesong; E, Mingyan

doi:10.1016/j.tranon.2021.101210

Cited by 14 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhuang M. et al used GNPs loaded with small interfering RNA (siRNA)-SP1 (AuNPs-si-SP1) for inducing radiosensitization during radiotherapy against lung cancer. Au nanoparticles (GNPs) in this conjugate are efficient in augmenting radiosensitivity in lung cancer cells, which is accompanied by mitigated cell viability which subsequently fosters cell cycle arrest and induces programmed cell death [ 82 ]. Furthermore, the loaded siRNA in AuNPs-si-SP1 also shows a significantly better performance in suppressing SP1 mRNA and protein expression in A549 lung cancer cells when compared to the free siRNA-SP1 [ 82 , 83 ].…”

Section: Experimental Studies On Nanoparticles Combined With Radiothe...mentioning

confidence: 99%

“…Au nanoparticles (GNPs) in this conjugate are efficient in augmenting radiosensitivity in lung cancer cells, which is accompanied by mitigated cell viability which subsequently fosters cell cycle arrest and induces programmed cell death [ 82 ]. Furthermore, the loaded siRNA in AuNPs-si-SP1 also shows a significantly better performance in suppressing SP1 mRNA and protein expression in A549 lung cancer cells when compared to the free siRNA-SP1 [ 82 , 83 ]. AuNPs-si-SP1 in tumor-bearing mice models can significantly impair the proliferation of cancer cells in solid tumors via inhibiting SP1, and upregulates granzyme B (GZMB) [ 82 ].…”

Section: Experimental Studies On Nanoparticles Combined With Radiothe...mentioning

confidence: 99%

“…Furthermore, the loaded siRNA in AuNPs-si-SP1 also shows a significantly better performance in suppressing SP1 mRNA and protein expression in A549 lung cancer cells when compared to the free siRNA-SP1 [ 82 , 83 ]. AuNPs-si-SP1 in tumor-bearing mice models can significantly impair the proliferation of cancer cells in solid tumors via inhibiting SP1, and upregulates granzyme B (GZMB) [ 82 ]. Chiang C. et al have explored ‘Au nanoparticles’ in the tumor cell-targeting radiotherapy of glioblastoma multiforme (GBM), a malignant tumor with a low survival rate of 10 to 14 months after diagnosis [ 84 ].…”

Section: Experimental Studies On Nanoparticles Combined With Radiothe...mentioning

confidence: 99%

See 2 more Smart Citations

Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia

et al. 2022

View full text Add to dashboard Cite

Radiotherapy and internal radioisotope therapy (brachytherapy) induce tumor cell death through different molecular signaling pathways. However, these therapies in cancer patients are constrained by dose-related adverse effects and local discomfort due to the prolonged exposure to the surrounding tissues. Technological advancements in nanotechnology have resulted in synthesis of high atomic elements such as nanomaterials, which can be used as radiosensitizers due to their photoelectric characteristics. The aim of this review is to elucidate the effects of novel nanomaterials in the field of radiation oncology to ameliorate dose-related toxicity through the application of ideal nanoparticle-based radiosensitizers such as Au (gold), Bi (bismuth), and Lu (Lutetium-177) for enhancing cytotoxic effects of radiotherapy via the high-Z effect. In addition, we discuss the role of nanoparticle-enhanced radiotherapy in alleviating tumor hypoxia through the nanodelivery of genes/drugs and other functional anticancer molecules. The implications of engineered nanoparticles in preclinical and clinical studies still need to be studied in order to explore potential mechanisms for radiosensitization by minimizing tumor hypoxia, operational/logistic complications and by overcoming tumor heterogeneity in radiotherapy/brachytherapy.

show abstract

Section: Experimental Studies On Nanoparticles Combined With Radiothe...mentioning

confidence: 99%

Section: Experimental Studies On Nanoparticles Combined With Radiothe...mentioning

confidence: 99%

Section: Experimental Studies On Nanoparticles Combined With Radiothe...mentioning

confidence: 99%

See 1 more Smart Citation

Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The siRNA-conjugated AuNPs also exhibited a combination of radiotherapy along with gene therapy [ 172 , 173 ]. Similarly, AuNPs can co-deliver DOX and siRNA for combinational CTX and gene therapy [ 174 , 175 ].…”

Section: Introductionmentioning

confidence: 99%

Next-generation engineered nanogold for multimodal cancer therapy and imaging: a clinical perspectives

2022

View full text Add to dashboard Cite

Cancer is one of the significant threats to human life. Although various latest technologies are currently available to treat cancer, it still accounts for millions of death each year worldwide. Thus, creating a need for more developed and novel technologies to combat this deadly condition. Nanoparticles-based cancer therapeutics have offered a promising approach to treat cancer effectively while minimizing adverse events. Among various nanoparticles, nanogold (AuNPs) are biocompatible and have proved their efficiency in treating cancer because they can reach tumors via enhanced permeability and retention effect. The size and shape of the AuNPs are responsible for their diverse therapeutic behavior. Thus, to modulate their therapeutic values, the AuNPs can be synthesized in various shapes, such as spheres, cages, flowers, shells, prisms, rods, clusters, etc. Also, attaching AuNPs with single or multiple targeting agents can facilitate the active targeting of AuNPs to the tumor tissue. The AuNPs have been much explored for photothermal therapy (PTT) to treat cancer. In addition to PTT, AuNPs-based nanoplatforms have been investigated for combinational multimodal therapies in the last few years, including photodynamic therapy, chemotherapy, radiotherapy, immunotherapy, etc., to ablate cancer cells. Thus, the present review focuses on the recent advancements in the functionalization of AuNPs-based nanoconstructs for cancer imaging and therapy using combinatorial multimodal approaches to treat various cancers. Graphical Abstract

show abstract

“…Accordingly, this study screened the potential genes with aberrant expression through the GSE43523 data set in GEO and found granzyme B (GzmB) among them. Prior research on GzmB primarily focused on the impacts of GzmB on tumour diseases [ 11 , 12 ], but did not point out its potential association with AR. However, Tschopp et al [ 13 ] have clearly pointed out GzmB as a novel allergic inflammatory mediator able to induce blood basophils and release in large quantities in asthma cases.…”

Section: Introductionmentioning

confidence: 99%

Influences of miR-378a-3p on the Pathogenesis of Allergic Rhinitis via GzmB-Mediated Inflammatory Reaction

Wang

Zhang

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background and objective. Allergic rhinitis (AR), a highly frequently seen chronic inflammation of the upper respiratory tract, shows a growing global incidence. The modern research on the pro-inflammatory mechanism molecularly offers a new direction for the early therapy AR in the future and also reveals the potential therapeutic targets of IT, which is known as the breakthrough of diagnosis and therapy of AR. Through the screening of GSE43523 data set in GEO, we discovered aberrant expression of granzyme B (GzmB) gene in AR cases. Online data analysis revealed the possible regulation of upstream target microRNA-378a-3p (miR-378a-3p) on its expression. Accordingly, this study analysed the impacts of miR-378a-3p and GzmB on AR to set the foundation for the follow-up associated research and offer novel ideas and directions for the future diagnosis and therapy of AR. Methods. Totally, 24 BALB/c mice were assigned to the AR group, control group, GzmB group, and blank group (each n = 6). The blank group was normally fed without treatment, and the other three groups were treated by ovalbumin (OVA) to induce AR models, in which the GzmB group was intranasally injected with lentiviral vector suppressing GzmB expression during the second immunization, while the control group was given the GzmB-blank vector. The times of AR pathological behaviours such as sneezing and scratching the nose of mice were observed and counted. The nasal lavage fluid of each mouse was acquired, and then, the mouse was executed by cervical dislocation, followed by collection of blood and nasal mucosa tissues. Then, ELISA was adopted for quantifying immunoglobulin E (IgE), interleukin (IL)-4, IL-6, and histamine (HA), and nasal mucosa tissues were treated by HE and TUNEL staining to observing their histopathological manifestations. PCR and western blot (WB) were adopted for quantifying GzmB and miR-378a-3p. Additionally, with NP69 cells, dual luciferase reporter (DLR) assay was carried out for determining the targeting association of GzmB with miR-378a-3p. Another 24 mice were assigned to the AR group, GzmB group, miR-378a-3p group, and GzmB+ miR-378a-3p group (each n = 6). The AR and GzmB groups were treated as above. The miR-378a-3p group was intervened by lentiviral vector suppressing miR-378a-3p, while the GzmB+ miR-378a-3p group was given GzmB and lentiviral vector suppressing miR-378a-3p meantime. A rescue assay was conducted through repeating the above tests. Results. The times of sneezing and rubbing the nose and the levels of IgE, IL-4, IL-6, and HA were similar between the control and AR groups (all P > 0.05 ), and these items of the two groups were all higher than those of the blank and GzmB groups (all P < 0.05 ). However, no notable difference was observed in IL-4 and IL-6 levels between the GzmB and blank groups (both P > 0.05 ), while higher levels of other detection results were found in the former group than in the latter (all P < 0.05 ). The staining results revealed obvious congestion, oedema, and necrosis structures in the nasal mucosa epithelium of the control and AR groups and also revealed a large number of infiltrating eosinophils and notable increase of apoptotic nasal mucosa epithelial cells. The GzmB group showed notably improved nasal mucosa tissues, and its infiltration and apoptosis of eosinophils were more notable than those of the blank group, but notably weaker than those of the AR and control groups. Additionally, the PCR and WB results revealed similar miR-378a-3p and GzmB levels in nasal mucosa between the control and AR groups (both P > 0.05 ), and a notable decrease of miR-378a-3p and a notable increase of GzmB in both groups (both P < 0.05 ). The DLR assay revealed notably suppressed fluorescence activity of GzmB-WT in NP69 cells after transfection of miR-378a-3p mimics ( P < 0.05 ) and notably down regulated GzmB protein after increase of miR-378a-3p (P<0.05). Finally, the rescue assay revealed that downregulating miR-378a-3p aggravated the pathological changes of AR ( P < 0.05 ) and also completely reversed the impacts of inhibiting GzmB on the pathological behaviours of AR mice. Conclusions. MiR-378a-3p can accelerate the pathological development of AR through targeted inhibition on the release of pro-inflammatory factors such as IgE and HA activated by GzmB, so it is a promising molecular target of AR therapy and offers a novel research direction for the complete cure of AR.

show abstract

Radiosensitizing effect of gold nanoparticle loaded with small interfering RNA-SP1 on lung cancer

Cited by 14 publications

References 29 publications

Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia

Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia

Next-generation engineered nanogold for multimodal cancer therapy and imaging: a clinical perspectives

Influences of miR-378a-3p on the Pathogenesis of Allergic Rhinitis via GzmB-Mediated Inflammatory Reaction

Contact Info

Product

Resources

About